We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Bee Venom Nanoparticles Reduce Tumors in Animal Experiments

By LabMedica International staff writers
Posted on 25 Aug 2009
Melittin, the toxic component of bee venom, has been incorporated into nanoparticles such that when injected into mice triggered death of cancer cells and remission of tumors of both breast cancers and melanomas as well as destruction of precancerous skin lesions. More...
Melittin, a peptide consisting of 26 amino acids, is the principal active component of bee venom (apitoxin) and is a potent antimicrobial compound and a powerful stimulator of phospholipase A2.

Investigators at Washington University School of Medicine (St. Louis, MO, USA) affectionately nicknamed the nanoparticles prepared from perfluorocarbon and melittin "nanobees.” These particles could be further modified to incorporate specific targeting molecules such as antibodies or receptors. The nanobee format has two major features. It sequesters the melittin and protects the body from its toxic effects. At the same time, the nanoparticles are resistant to the action of proteolytic enzymes in the blood that would otherwise quickly destroy the melittin.

To test the efficacy of the nanobees the investigators worked with mouse models for both human breast cancer and melanoma. Results published in the August 10, 2009, online edition of the Journal of Clinical Investigation revealed that four to five injections of generic nanobees over several days, slowed growth of breast cancer tumors by nearly 25%, while the size of melanoma tumors decreased by 88% compared to untreated tumors. Molecularly targeted nanobees selectively delivered melittin to multiple tumor targets, including endothelial and cancer cells. The transfer process did not disrupt the surface membrane of cells but did trigger apoptosis and in animals caused regression of precancerous dysplastic lesions.

"Melittin has been of interest to researchers because in high enough concentration it can destroy any cell it comes into contact with, making it an effective antibacterial and antifungal agent and potentially an anticancer agent," said senior author Dr. Paul Schlesinger, associate professor of cell biology and physiology at Washington University School of Medicine. "Cancer cells can adapt and develop resistance to many anticancer agents that alter gene function or target a cell's DNA, but it is hard for cells to find a way around the mechanism that melittin uses to kill."

"Nanobees are an effective way to package the useful, but potentially deadly, melittin, sequestering it so that it neither harms normal cells nor gets degraded before it reaches its target," said Dr. Schlesinger. "Potentially, these could be formulated for a particular patient. We are learning more and more about tumor biology, and that knowledge could soon allow us to create nanoparticles targeted for specific tumors using the nanobee approach."

Related Links:
Washington University School of Medicine




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.